# reload+after+2024-01-23 00:44:17.355067
address1§11 Commerce Drive
address2§First Floor
city§Cranford
state§NJ
zip§07016
country§United States
phone§908 967 6677
website§https://citiuspharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.
fullTimeEmployees§22
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Leonard L. Mazur', 'age': 78, 'title': 'Co-Founder, CEO, Chairman & Secretary', 'yearBorn': 1945, 'fiscalYear': 2022, 'totalPay': 570000, 'exercisedValue': 0, 'unexercisedValue': 76333}, {'maxAge': 1, 'name': 'Mr. Myron Z. Holubiak', 'age': 76, 'title': 'Co-Founder & Executive Vice Chairman', 'yearBorn': 1947, 'fiscalYear': 2022, 'totalPay': 620000, 'exercisedValue': 0, 'unexercisedValue': 76333}, {'maxAge': 1, 'name': 'Mr. Jaime  Bartushak', 'age': 55, 'title': 'Chief Business Officer, CFO & Chief Accounting Officer', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 527967, 'exercisedValue': 0, 'unexercisedValue': 44333}, {'maxAge': 1, 'name': 'Dr. Myron S. Czuczman M.D.', 'age': 63, 'title': 'Executive VP & Chief Medical Officer', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 550917, 'exercisedValue': 0, 'unexercisedValue': 7500}, {'maxAge': 1, 'name': 'Mr. Gary F. Talarico', 'age': 68, 'title': 'Executive Vice President of Operations', 'yearBorn': 1955, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Ilanit  Allen', 'title': 'Vice President of Investor Relations & Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Alan  Lader Ph.D.', 'title': 'Senior VP and Head of Clinical Operations & Quality Assurance', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Dhananjay G. Wadekar', 'age': 69, 'title': 'Senior Vice President of Business Strategy', 'yearBorn': 1954, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kelly  Creighton Ph.D.', 'title': 'Executive Vice President of Chemistry, Manufacturing & Controls', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Nikolas  Burlew', 'title': 'Executive Vice President of Quality Assurance', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§9
compensationRisk§7
shareHolderRightsRisk§1
overallRisk§6
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.352
currency§USD
dateShortInterest§1702598400
forwardEps§0.49
exchange§NCM
quoteType§EQUITY
shortName§Citius Pharmaceuticals, Inc.
longName§Citius Pharmaceuticals, Inc.
firstTradeDateEpochUtc§1412256600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§c2faef45-30de-37ba-b921-6b91e4daf573
gmtOffSetMilliseconds§-18000000
targetHighPrice§8.0
targetLowPrice§4.0
targetMeanPrice§5.33
targetMedianPrice§4.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§3
quickRatio§4.582
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
